Kalshi and AppliedXL launch CFTC-regulated biotech prediction markets
Kalshi partnered with public intelligence company AppliedXL to launch a pilot program of CFTC-regulated prediction markets on clinical trial outcomes and FDA regulatory decisions, the companies said on Thursday, July 16, 2026. The contracts let traders wager on biotechnology results in a format similar to sports betting. The healthcare vertical is new for the platform, which has previously focused on political, economic, and sports event markets.
The biotech pilot gives Kalshi a regulated vertical outside the sports and politics categories now in congressional crosshairs. A bipartisan Senate bill introduced in March would ban sports event contracts on CFTC-registered platforms, threatening the revenue base Kalshi shares with Polymarket. The AppliedXL partnership supplies specialized data infrastructure for FDA and trial outcomes, a capability Kalshi lacks in-house.
Traders gain a hedging tool for biotech portfolios, but liquidity will depend on whether institutional investors embrace event contracts alongside traditional equity options. The CFTC registration means these markets avoid the state-by-state legal fights consuming Kalshi's sports vertical in Michigan, New York, Illinois, and New Mexico. A thin launch would confirm that niche scientific topics struggle to generate retail flow without partisan or sporting energy. A robust one would give Kalshi's lobbyists a diversified use case to defend against charges that prediction markets are merely wagering.
Kalshi's biotech pilot joins a recent vertical-building sprint that already produced flight cancellation contracts for corporate hedgers and a gold-and-silver perpetual futures filing, as the exchange races to diversify beyond the sports and politics contracts now threatened by a bipartisan Senate ban.